GlassScriptPhysician profile
Ashley Hall Tapscott
NPI 1124282587
$425,124.14
in general payments reported to CMS, 2019-2025
39 companies · $19K in 2025
The $19K reported for 2025 was more than what 96% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $6,261 · 2021: $28K · 2022: $68K · 2023: $174K · 2024: $64K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $123K · Honoraria: $68K · Travel and Lodging: $42K · Consulting Fee: $14K · Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $122,617.11 |
| Honoraria | $67,850.00 |
| Travel and Lodging | $41,604.17 |
| Consulting Fee | $14,040.00 |
| Food and Beverage | $11,143.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $121,212.76 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Endo Pharmaceuticals INC. | $109,136.39 | 2019-2024 | Xiaflex, Aveed, Edex |
| Sumitomo Pharma America, INC. | $102,033.06 | 2023-2025 | Gemtesa |
| Urovant Sciences INC | $28,205.40 | 2021-2022 | |
| Endo USA, INC. | $21,909.12 | 2024-2025 | Xiaflex, Aveed |
| Coloplast Corp | $14,101.30 | 2019-2025 | Titan |
| Astellas Pharma US INC | $12,341.40 | 2019-2023 | Xtandi |
| Metuchen Pharmaceuticals | $10,475.18 | 2019-2020 | |
| Axonics, INC. | $1,989.59 | 2022-2024 | Axonics, Bulkamid |
| Olympus America INC. | $742.39 | 2020-2025 | Itind System |
| Boston Scientific Corporation | $588.82 | 2022-2024 | Ams 700, Spaceoar Vue System - 10ml, Ams 800 Artificial Urinary Sphincter |
| Teleflex LLC | $315.88 | 2021-2025 | Urolift |
| Halozyme INC | $259.74 | 2023 | |
| Rigicon,INC. | $241.63 | 2022-2024 | Rigi10 Malleable Penile Prosthesis |
| Pfizer INC. | $186.24 | 2019-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Tapscott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.